Education
About Us
Working with TipRanks
Follow Us
ANI Pharmaceuticals Inc (ANIP)
NASDAQ:ANIP
ANIP Stock Chart & Stats
Day’s Range― - ―
52-Week Range$52.50 - $70.48
Previous CloseN/A
Volume18.69K
Average Volume (3M)385.13K
Market Cap
$1.50B
Enterprise Value$1.58B
Total Cash (Recent Filing)$41.16M
Total Debt (Recent Filing)$18.09M
Price to Earnings (P/E)―
Beta0.48
Next Earnings
May 09, 2025EPS Estimate
1.38Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.13
Shares Outstanding21,574,175
10 Day Avg. Volume332,990
30 Day Avg. Volume385,132
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)2.20
Price to Cash Flow (P/CF)21.30
P/FCF Ratio16.90
Enterprise Value/Market Cap1.05
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit2.57
Enterprise Value/Ebitda28.77
Forecast
1Y Price Target
$81.57Price Target Upside17.13% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
---
Bulls Say, Bears Say
Bulls Say
Generics GrowthStrong generics trends are highlighted with volumes up 35% year-over-year, indicating positive momentum for Ani Pharmaceuticals.
Product ApprovalThe FDA approved an expanded Iluvien label, adding chronic non-infection uveitis affecting the posterior segment (NIU-PS) to the current DME indication, which came earlier than expected and reflects continued ANI regulatory execution.
Product GrowthCortrophin Gel, ANI’s lead product, has a long runway for growth with opportunities in ophthalmology and acute gouty arthritis.
Bears Say
Product Launch RisksRisks include the possibility of generic launches falling short, limited track record for Iluvien/Yutiq, and potential failure to drive Cortrophin volumes.
Seasonality ImpactRare disease segment is experiencing a sequential step-down due to seasonality, which seems appropriately reflected in consensus estimates.
Valuation ConcernsThe stock is trading at a valuation more suitable for a pure generics company, despite significant contributions and growth from the rare disease portfolio.
---
Ownership Overview
11.08% Insiders
19.77% Mutual Funds
0.84% Other Institutional Investors
49.64% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ANIP FAQ
What was ANI Pharmaceuticals Inc’s price range in the past 12 months?
ANI Pharmaceuticals Inc lowest stock price was $52.50 and its highest was $70.48 in the past 12 months.
What is ANI Pharmaceuticals Inc’s market cap?
ANI Pharmaceuticals Inc’s market cap is $1.50B.
When is ANI Pharmaceuticals Inc’s upcoming earnings report date?
ANI Pharmaceuticals Inc’s upcoming earnings report date is May 09, 2025 which is in 14 days.
How were ANI Pharmaceuticals Inc’s earnings last quarter?
ANI Pharmaceuticals Inc released its earnings results on Feb 28, 2025. The company reported $1.63 earnings per share for the quarter, beating the consensus estimate of $1.435 by $0.195.
Is ANI Pharmaceuticals Inc overvalued?
According to Wall Street analysts ANI Pharmaceuticals Inc’s price is currently Undervalued.
Does ANI Pharmaceuticals Inc pay dividends?
ANI Pharmaceuticals Inc does not currently pay dividends.
What is ANI Pharmaceuticals Inc’s EPS estimate?
ANI Pharmaceuticals Inc’s EPS estimate is 1.38.
How many shares outstanding does ANI Pharmaceuticals Inc have?
ANI Pharmaceuticals Inc has 21,574,175 shares outstanding.
What happened to ANI Pharmaceuticals Inc’s price movement after its last earnings report?
ANI Pharmaceuticals Inc reported an EPS of $1.63 in its last earnings report, beating expectations of $1.435. Following the earnings report the stock price went up 13.393%.
Which hedge fund is a major shareholder of ANI Pharmaceuticals Inc?
Currently, no hedge funds are holding shares in ANIP
---
ANI Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$81.57 (17.13% Upside)
$81.57 (17.13% Upside)
Blogger Sentiment
Bullish
ANIP Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 113.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $323.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.2%
Last 30 Days ▲ 15.4%
Last 30 Days ▲ 15.4%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
6.43%
12-Months-Change
Fundamentals
Return on Equity
-4.86%
Trailing 12-Months
Asset Growth
41.94%
Trailing 12-Months
Company Description
ANI Pharmaceuticals Inc
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, injectables, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract development and manufacturing of pharmaceutical products for other companies. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. The company was incorporated in 2001 and is headquartered in Baudette, Minnesota.
---
ANIP Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
ANI Pharmaceuticals demonstrated strong performance in 2024, with record results and increased guidance for 2025. The company showed significant growth in its Rare Disease and Generics businesses and completed a strategic acquisition. However, there are challenges related to market access for ILUVIEN and YUTIQ and potential disruptions due to manufacturing transitions. Despite these challenges, the positive momentum and strategic initiatives in place suggest a cautiously optimistic outlook.Read More>---
ANIP Stock 12 Month Forecast
Average Price Target
$81.57
▲(17.13% Upside)
Technical Analysis
Dynavax
―
Pacira Pharmaceuticals
―
Supernus Pharmaceuticals
―
Amphastar Pharmaceuticals
―
Collegium Pharmaceutical
―
Best Analysts Covering ANIP
1 Year
1 Year Success Rate
12/14 ratings generated profit
1 Year Average Return
+24.72%
reiterated a buy rating last month
Copying Oren Livnat's trades and holding each position for 1 Year would result in 85.71% of your transactions generating a profit, with an average return of +24.72% per trade.
---